Inverse relationship between PSA and IL-8 in prostate cancer: An insight into a NF-κB-mediated mechanism

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Xu, Yong ^a   Fang, Fang ^b   St Clair, Daret K ^a   St Clair, William H ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; RELB PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; RNA INTERFERENCE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; METABOLISM; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; INTERLEUKIN-8; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; TRANSCRIPTION FACTOR RELB; UP-REGULATION;

EID: 84863268612     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032905     Document Type: Article

References (37)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2010) SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER web site, 2011.http://seer.cancer.gov/csr/1975_2008/.
2. Karin M, Ben-Neriah Y, (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-630.
3. Bonizzi G, Karin M, (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
4. Aggarwal BB, Vijayalekshmi RV, Sung B, (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15: 425-430.
5. Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, et al. (2009) RelB enhances prostate cancer growth: implications for the role of the NF-κB alternative pathway in tumorigenicity. Cancer Res 69: 3267-3271.
6. Nourbakhsh M, Kalble S, Dorrie A, Hauser H, Resch K, et al. (2001) The NF-kappa b repressing factor is involved in basal repression and interleukin (IL)-1-induced activation of IL-8 transcription by binding to a conserved NF-kappa b-flanking sequence element. J Biol Chem 276: 4501-4508.
7. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G, (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72: 1605-1621.
8. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, et al. (2007) Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67: 6854-6862.
9. Waugh DJ, Wilson C, (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741.
10. Karin M, (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
11. Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, et al. (2006) Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys 65: 975-981.
12. Singh RK, Lokeshwar BL, (2009) Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 8: 57.
13. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, et al. (2002) The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17: 525-535.
14. Antwerp DJV, Martin SJ, Kafri T, Green DR, Verma IM, (1996) Suppression of TNF-α-induced apoptosis by NF-κB. Science 274: 787-789.
15. Xiao G, Harhaj EW, Sun SC, (2001) NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 7: 401-409.
16. Waugh DJ, Wilson C, (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741.
17. Balk SP, Ko YJ, Bubley GJ, (2003) Biology of prostate-specific antigen. J Clin Oncol 21: 383-391.
18. Herschman JD, Smith DS, Catalona WJ, (1997) Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 50: 239-243.
19. Freedland SJ, (2011) Screening, risk Assessment, and the approach to therapy in patients with prostate cancer. Cancer 117: 1123-1135.
20. Thompson I, Pauler D, Goodman P, Tangen CM, Lucia MS, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N Engl J Med 350: 2239-2246.
21. Caruso DJ, Carmack AJ, Lokeshwar VB, Duncan RC, Soloway MS, et al. (2008) Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res 14: 4111-4118.
22. Karin M, Lin A, (2002) NF-κB at the crossroads of life and death. Nature Immunol 3: 221-227.
23. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466.
24. Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F, (2005) Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93: 1019-1023.
25. Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, et al. (2006) RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 25: 1554-1559.
26. Xu Y, Fang F, St Clair DK, Josson S, Sompol P, et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 6: 2048-2056.
27. Xu Y, Fang F, St Clair DK, Sompol P, Josson S, et al. (2008) SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 7: 2367-2376.
28. Taplin ME, (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4: 236-244.
29. Feldman BJ, Feldman D, (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
30. Knudsen KE, Scher HI, (2009) Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15: 4792-4798.
31. Karin M, (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1: a000141.
32. Vogel CF, Sciullo E, Li W, Wong P, Lazennec G, et al. (2007) RelB, a new partner of aryl hydrocarbon receptor-mediated transcription. Mol Endocrinol 21: 2941-2955.
33. Cinar B, Yeung F, Konaka H, Mayo MW, Freeman MR, et al. (2004) Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Biochem J 379: 421-431.
34. Habraken Y, Piette J, (2006) NF-kappaB activation by double-strand breaks. Biochem Pharmacol 72: 1132-1141.
35. Ahmed KM, Li JJ, (2007) ATM-NF-kappaB connection as a target for tumor radiosensitization. Curr Cancer Drug Targets 4: 335-342.
36. Korkaya H, Liu S, Wicha MS, (2011) Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancers Inflammatory Roots. Clin Cancer Res 2011 Jun 17 [Epub ahead of print].
37. Xiao G, Harhaj EW, Sun SC, (2001) NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2: 401-409.